Evidence map›Paper›PMID 32472653›Full record

SynthesisStem cells translational medicine2020

Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome.

Wenchun Qu, Zhen Wang, Joshua M Hare, Guojun Bu, Jorge M Mallea, Jorge M Pascual, Arnold I Caplan, Joanne Kurtzberg, Abba C Zubair, Eva Kubrova and 8 more

Registry-linked trialOpen access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Stem cells translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06163833 (MATRIx), which is not on this map. Cited by 69 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 11 pooled it
18.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06163833 phase2recruitingnot on this mapstarted 2023, after this paper: background citation

MATRIx: MesenchymAl Stromal Cells for Traumatic bRain Injury

TypeinterventionalSponsorFondazione IRCCS San Gerardo dei TintoriRan2023 to 2026Enrolled78ConditionsTraumatic Brain Injury With Loss of ConsciousnessArmsMesenchymal stromal cell low dosage-80*10^6 cells, Mesenchymal stromal cell low dosage-160*10^6 cells, Placebo-storage solution
3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 11 syntheses or guidelines pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 1 country.

Wenchun QuDepartment of Pain Medicine, Mayo Clinic, Jacksonville, Florida, USA.ORCID 0000-0003-2402-8318
Zhen WangEvidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota, USA.
Joshua M HareInterdisciplinary Stem Cell Institute and Cardiology Division, Department of Medicine, University of Miami, Miller School of Medicine, Miami, Florida, USA.ORCID 0000-0002-7751-5032
Guojun BuCenter for Regenerative Medicine, Mayo Clinic, Jacksonville, Florida, USA.
Jorge M MalleaDivision of Pulmonary, Allergy and Sleep Medicine, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA.
Jorge M PascualDivision of Pulmonary, Allergy and Sleep Medicine, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA.
Arnold I CaplanSkeletal Research Center, Biology Department, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0002-8677-6621
Joanne KurtzbergMarcus Center for Cellular Cures, Duke University Medical Center, Durham, North Carolina, USA.
Abba C ZubairCenter for Regenerative Medicine, Mayo Clinic, Jacksonville, Florida, USA.ORCID 0000-0003-4827-4740
Eva KubrovaDepartment of Physical Medicine and Rehabilitation, Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Erica Engelberg-CookDepartment of Pain Medicine, Mayo Clinic, Jacksonville, Florida, USA.
Tarek NayfehEvidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota, USA.
Vishal P ShahDepartment of Preventative, Occupational, and Aerospace Medicine, Mayo Clinic, Rochester, Minnesota, USA.
James C HillDepartment of Preventative, Occupational, and Aerospace Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Michael E WolfDepartment of Preventative, Occupational, and Aerospace Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-6385-9128
Larry J ProkopMayo Clinic Library, Rochester, Minnesota, USA.
M Hassan MuradEvidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota, USA.
Fred P SanfilippoDepartment of Pathology and Laboratory Medicine, Department of Health Policy and Management, Rollins School of Public Health, Emory University, The Marcus Foundation, Atlanta, Georgia, USA.
Mayo Clinic · USWinnMed · USMayo Clinic in Florida · USJacksonville College · USCase Western Reserve University · USDuke Medical Center · USEmory University · USMayo Clinic in Arizona · USUniversity of Miami · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe cases of COVID-19 infection, often leading to death, have been associated with variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal stromal cells (MSCs) is a potential treatment for COVID-19 ARDS based on preclinical and clinical studies supporting the concept that MSCs modulate the inflammatory and remodeling processes and restore alveolo-capillary barriers. The authors performed a systematic literature review and random-effects meta-analysis to determine the potential value of MSC therapy for treating COVID-19-infected patients with ARDS. Publications in all languages from 1990 to March 31, 2020 were reviewed, yielding 2691 studies, of which nine were included. MSCs were intravenously or intratracheally administered in 117 participants, who were followed for 14 days to 5 years. All MSCs were allogeneic from bone marrow, umbilical cord, menstrual blood, adipose tissue, or unreported sources. Combined mortality showed a favorable trend but did not reach statistical significance. No related serious adverse events were reported and mild adverse events resolved spontaneously. A trend was found of improved radiographic findings, pulmonary function (lung compliance, tidal volumes, PaO

Indexed as

Mesenchymal Stem Cell TransplantationBetacoronavirusCell- and Tissue-Based TherapyCoronavirus InfectionsCOVID-19CytokinesHumansLungMesenchymal Stem CellsPandemicsPneumonia, ViralRespiratory Distress SyndromeSARS-CoV-2Cytokinesacute respiratory distress syndromeCOVID-19mesenchymal stromal cellsmortalitysystematic review

Identifiers

PMID32472653
PMCPMC7300743
OpenAlexW3029424687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.